IL6R and COVID-19: Inhibition of both membrane and soluble IL6R using monoclonal antibodies such as tocilizumab or sarilumab (collectively known as IL-6 receptor antagonists, IL6RAs) have been successfully trialled in critically ill patients with Coronavirus Disease 2019 (COVID-19) and are now considered a standard treatment [9–11].